Theravance Biopharma (NASDAQ: TBPH) director granted shares and 13,398-share option

Rhea-AI Filing Summary

Theravance Biopharma director Laurie Smaldone Alsup received new equity compensation in the form of shares and options. On 2026-06-12, she was granted 6,009 Ordinary Shares at no cost, increasing her direct holdings to 80,989 shares.

On the same date, she was also granted a Share Option covering 13,398 Ordinary Shares at an exercise price of $16.6400 per share, expiring on 2036-06-11. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant date, with any remaining unvested portion vesting on the date of the next annual shareholder meeting, subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Smaldone Alsup Laurie

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	13,398	$0.00	--
Grant/Award	Ordinary Shares	6,009	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 13,398 shares (Direct, null); Ordinary Shares — 80,989 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 6,009 Ordinary Shares Shares held after grant: 80,989 Ordinary Shares Option grant size: 13,398 shares +2 more

5 metrics

Shares granted 6,009 Ordinary Shares Grant to Laurie Smaldone Alsup on 2026-06-12

Shares held after grant 80,989 Ordinary Shares Direct holdings following share award

Option grant size 13,398 shares Share Option (Right to Buy) granted 2026-06-12

Option exercise price $16.6400 per share Exercise price for 13,398-share option

Option expiration June 11, 2036 Expiration date of newly granted option

Key Terms

Share Option (Right to Buy), Ordinary Shares, grant/award acquisition, exercise price, +2 more

6 terms

Share Option (Right to Buy) financial

"Share Option (Right to Buy) with 13,398 underlying Ordinary Shares"

Ordinary Shares financial

"Grant of 6,009 Ordinary Shares and resulting 80,989-share holding"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

grant/award acquisition financial

"Transaction classified as grant/award acquisition under code A"

exercise price financial

"Share Option has an exercise price of $16.6400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option’s expiration date is June 11, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous month of service financial

"Option vests 1/12 after each continuous month of service"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 09:41 PM Accepted by SEC EDGAR 06/16/2026 - 09:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smaldone Alsup Laurie

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/12/2026		A		6,009	A	$0	80,989	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$16.64	06/12/2026		A		13,398		(1)	06/11/2036	Ordinary Shares	13,398	$0	13,398	D

Explanation of Responses:

1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

	/s/ Brett A. Grimaud, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Laurie Smaldone Alsup receive from Theravance Biopharma (TBPH)?

Laurie Smaldone Alsup received 6,009 Ordinary Shares and a stock option for 13,398 Ordinary Shares. The option has an exercise price of $16.6400 per share and represents additional potential ownership if exercised in the future, subject to vesting conditions.

How many Theravance Biopharma (TBPH) shares does Laurie Smaldone Alsup hold after this Form 4?

After the reported grants, Laurie Smaldone Alsup directly holds 80,989 Ordinary Shares. She also holds a newly granted option over 13,398 Ordinary Shares at a $16.6400 exercise price, which may be exercised as and when it vests over time.

What are the vesting terms of Laurie Smaldone Alsup’s new Theravance Biopharma stock option?

The option vests as to 1/12 of the 13,398 underlying Ordinary Shares after each month of continuous service following the grant date. Any remaining unvested shares then vest on the date of the next annual shareholder meeting, provided she remains in continuous service.

Is Laurie Smaldone Alsup’s Form 4 transaction in TBPH a market purchase or a grant?

The Form 4 shows a grant or award, not a market purchase. She acquired 6,009 Ordinary Shares at a price of $0.0000 per share and a stock option for 13,398 shares as part of compensation, both classified as grant or award acquisitions.

What is the exercise price and expiration date of Laurie Smaldone Alsup’s TBPH stock option?

The granted Share Option allows purchase of 13,398 Ordinary Shares at an exercise price of $16.6400 per share. The option expires on June 11, 2036, giving a long-term window to exercise vested portions, subject to the stated vesting schedule and service conditions.

Does the Form 4 for TBPH indicate any stock sales by Laurie Smaldone Alsup?

The Form 4 indicates only acquisitions, not sales. It reports one grant of 6,009 Ordinary Shares and one grant of a stock option over 13,398 Ordinary Shares. The transaction summary shows acquire transactions only, with no sell or dispose entries reported.